Compare FGNX & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGNX | NSPR |
|---|---|---|
| Founded | 1932 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 40.7M |
| IPO Year | 2014 | 2009 |
| Metric | FGNX | NSPR |
|---|---|---|
| Price | $8.28 | $0.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $35.00 | $4.00 |
| AVG Volume (30 Days) | ★ 112.3K | 90.1K |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,023,000.00 | $2,310,000.00 |
| Revenue This Year | $650.31 | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 20.70 | N/A |
| 52 Week Low | $1.59 | $0.63 |
| 52 Week High | $13.70 | $2.57 |
| Indicator | FGNX | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 58.03 |
| Support Level | $5.64 | $0.86 |
| Resistance Level | $9.17 | $1.03 |
| Average True Range (ATR) | 0.68 | 0.08 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 73.24 | 40.09 |
FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.